CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
CEML4::ALKFusionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaCrizotinibChoi et al., 2010
DCDK4EXPRESSIONPredictiveSupportsSensitivity/ResponseEstrogen-receptor Positive Breast CancerAlpelisibVora et al., 2014
DDDR2G253CPredictiveSupportsSensitivity/ResponseCancerDasatinibHammerman et al., 2011
DDDR2G505SPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDasatinibHammerman et al., 2011
DDDR2G774VPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDasatinibHammerman et al., 2011
DDDR2I638FPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDasatinibHammerman et al., 2011
DDDR2L239RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDasatinibHammerman et al., 2011
DDDR2L63VPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDasatinibHammerman et al., 2011
DEGFRExon 19 DeletionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibJi et al., 2006
DEGFRG719SPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibPaez et al., 2004
BEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,GefitinibFukihara et al., 2014
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibPaez et al., 2004
DERBB2D769HPredictiveSupportsSensitivity/ResponseBreast CancerNeratinib,LapatinibBose et al., 2013
DERBB2D769YPredictiveSupportsSensitivity/ResponseBreast CancerNeratinibBose et al., 2013
BFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaLestaurtinibSmith et al., 2004
BFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaSorafenibZhang et al., 2008
DFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaTyrphostin AG 1296Tse et al., 2002
DGATA2EXPRESSIONPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaBortezomib,FasudilKumar et al., 2012
DKRASG12DPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,DactolisibEngelman et al., 2008
BKRASG13DPredictiveSupportsSensitivity/ResponseColorectal CancerCetuximabDe Roock et al., 2010
BMGMTPromoter MethylationPredictiveSupportsSensitivity/ResponseGlioblastomaCarmustineEsteller et al., 2000
EMGMTPromoter MethylationPredictiveSupportsSensitivity/ResponseGlioblastomaO6-BenzylguanineEsteller et al., 2000
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseBreast CancerIzorlisibTanaka et al., 2011
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseBreast CancerIzorlisibTanaka et al., 2011
DPTENR233*PredictiveSupportsSensitivity/ResponseBreast CancerMTOR InhibitorCourtney et al., 2010
BKRASG12PrognosticDoes Not SupportBetter OutcomeColorectal CancerOgino et al., 2009
BCCND1OverexpressionPrognosticSupportsPoor OutcomeBreast CancerArnold et al., 2005
BCCND1OverexpressionPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaThomas et al., 2005
BCCND1OverexpressionPrognosticSupportsPoor OutcomeMantle Cell LymphomaJares et al., 2007
DCCND2OVEREXPRESSIONPrognosticSupportsPoor OutcomeStomach CancerTakano et al., 1999
DCCND2OVEREXPRESSIONPrognosticSupportsPoor OutcomeStomach CancerTakano et al., 1999
DCCND2OVEREXPRESSIONPrognosticSupportsPoor OutcomeStomach CancerTakano et al., 1999
DCCND2OVEREXPRESSIONPrognosticSupportsPoor OutcomeStomach CancerTakano et al., 1999
BCCNE1OverexpressionPrognosticSupportsPoor OutcomeBreast CancerKeyomarsi et al., 2002
BCCNE1OverexpressionPrognosticSupportsPoor OutcomeGastric Adenosquamous CarcinomaDonnellan et al., 1999
BEGFRT790MPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaDing et al., 2014
BEGFRT790MPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaLi et al., 2014
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaWhitman et al., 2001
BFLT3TKD MUTATIONPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaWhitman et al., 2008
BIDH1R132PrognosticSupportsPoor OutcomeMyelodysplastic SyndromeThol et al., 2010
BNOTCH1D1642HPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaWesthoff et al., 2009
BNOTCH1R2327WPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaWesthoff et al., 2009
BNOTCH1S2275FSPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaWesthoff et al., 2009
BNOTCH1V2444FSPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaWesthoff et al., 2009
BDNAJB1::PRKACAFusionDiagnosticSupportsPositiveFibrolamellar CarcinomaHoneyman et al., 2014
BBCL2reg_e@[IGH]::BCL2DiagnosticSupportsPositiveDiffuse Large B-cell LymphomaRosenwald et al., 2002
BRELAMPLIFICATIONDiagnosticSupportsPositiveDiffuse Large B-cell LymphomaRosenwald et al., 2002
BRUNX1MutationPredictiveSupportsResistanceAcute Myeloid LeukemiaCytarabineGaidzik et al., 2011
BEGFRExon 19 DeletionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinib,ErlotinibJackman et al., 2006
BTET2MutationPrognosticDoes Not SupportAcute Myeloid LeukemiaGaidzik et al., 2012
Page 6 of 96
PreviousNext